JP2018533956A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533956A5
JP2018533956A5 JP2018524721A JP2018524721A JP2018533956A5 JP 2018533956 A5 JP2018533956 A5 JP 2018533956A5 JP 2018524721 A JP2018524721 A JP 2018524721A JP 2018524721 A JP2018524721 A JP 2018524721A JP 2018533956 A5 JP2018533956 A5 JP 2018533956A5
Authority
JP
Japan
Prior art keywords
rna complex
sense strand
bonds
strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524721A
Other languages
English (en)
Japanese (ja)
Other versions
JP7027311B2 (ja
JP2018533956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001745 external-priority patent/WO2017085550A1/en
Publication of JP2018533956A publication Critical patent/JP2018533956A/ja
Publication of JP2018533956A5 publication Critical patent/JP2018533956A5/ja
Application granted granted Critical
Publication of JP7027311B2 publication Critical patent/JP7027311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524721A 2015-11-16 2016-11-15 MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療 Active JP7027311B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255878P 2015-11-16 2015-11-16
US62/255,878 2015-11-16
PCT/IB2016/001745 WO2017085550A1 (en) 2015-11-16 2016-11-15 Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3

Publications (3)

Publication Number Publication Date
JP2018533956A JP2018533956A (ja) 2018-11-22
JP2018533956A5 true JP2018533956A5 (cg-RX-API-DMAC7.html) 2019-12-26
JP7027311B2 JP7027311B2 (ja) 2022-03-01

Family

ID=58691443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524721A Active JP7027311B2 (ja) 2015-11-16 2016-11-15 MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療

Country Status (7)

Country Link
US (2) US10059949B2 (cg-RX-API-DMAC7.html)
EP (2) EP3377630A4 (cg-RX-API-DMAC7.html)
JP (1) JP7027311B2 (cg-RX-API-DMAC7.html)
KR (1) KR102727666B1 (cg-RX-API-DMAC7.html)
CN (1) CN108699556B (cg-RX-API-DMAC7.html)
CA (1) CA3005411C (cg-RX-API-DMAC7.html)
WO (1) WO2017085550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5795072B2 (ja) 2010-10-22 2015-10-14 ソンギュングヮン ユニバーシティ ファウンデーション フォー コーポレート コラボレーション Rna干渉を誘導する核酸分子及びその用途
JP6139671B2 (ja) 2012-05-22 2017-05-31 オリックス ファーマシューティカルズ インコーポレイテッドOlix Pharmaceuticals Inc. 細胞内貫通能を持ってrna干渉を誘導する核酸分子およびその用途
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ,インコーポレーテッド MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療
KR102825945B1 (ko) 2016-02-02 2025-06-30 올릭스 주식회사 Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
EP3411480A4 (en) 2016-02-02 2020-01-22 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4R , TRPA1, OR F2RL1
KR102339886B1 (ko) 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
JP7424728B2 (ja) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Rna干渉のための長鎖の二本鎖rna
CN115698287A (zh) * 2020-05-26 2023-02-03 奥利克斯医药有限公司 靶向MyD88的RNAi制剂以及其用途
KR20240169190A (ko) * 2023-05-23 2024-12-03 주식회사 에스앤케이테라퓨틱스 자가면역 질환 치료를 위한 신규 MyD88 억제제 및 이의 용도

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
US20080188430A1 (en) 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
WO2003035876A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
EP3222724B1 (en) 2002-08-05 2018-10-31 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
CN100558893C (zh) * 2003-09-18 2009-11-11 Isis药物公司 eIF4E表达的调节
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
WO2005079533A2 (en) 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
WO2005087926A2 (en) 2004-03-05 2005-09-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
EP2365077B1 (en) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP1793835A4 (en) 2004-09-10 2010-12-01 Somagenics Inc SMALL INTERFERING RNA EFFECTIVELY INHIBITING VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
CN101133074B (zh) 2004-09-24 2012-05-30 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
NZ563845A (en) 2005-04-08 2010-09-30 Marina Biotech Inc RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
EP1891216B1 (en) 2005-05-25 2012-02-22 The University Of York Hybrid interfering rna
MX2007016083A (es) 2005-06-24 2008-03-10 Intervet Int Bv Vacunas quimericas inactivadas y metodos relacionados de uso.
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
EP1986609A2 (en) 2006-01-26 2008-11-05 University of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
US20070218495A1 (en) 2006-03-16 2007-09-20 Dharmacon, Inc. Methods, libraries and computer program products for gene silencing with reduced off-target effects
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
EP2468864A1 (en) 2007-03-02 2012-06-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting VEGF family gene expression and uses thereof
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008150897A2 (en) 2007-05-31 2008-12-11 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
US20090004668A1 (en) 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
EP2316943B1 (en) * 2007-07-05 2013-06-19 Novartis AG DSRNA for treating viral infection
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009020344A2 (en) 2007-08-06 2009-02-12 Postech Acad Ind Found Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
EP3121281B1 (en) 2007-08-27 2021-03-31 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
EP2195428B1 (en) 2007-09-19 2013-12-11 Applied Biosystems, LLC SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
US20090131358A1 (en) 2007-11-15 2009-05-21 Alcon Research, Ltd. LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도
AU2009215795A1 (en) * 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
WO2010011346A1 (en) 2008-07-24 2010-01-28 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
WO2010017154A2 (en) * 2008-08-04 2010-02-11 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 3 expression by antisense oligonucleotides
WO2010017436A2 (en) 2008-08-08 2010-02-11 Idera Pharmaceuticals, Inc. Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
US8580562B2 (en) 2008-09-08 2013-11-12 Fukuoka University Inhibitory RNA for modulating the molecular function of ZFAT gene
JP2012502991A (ja) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚適用におけるrna干渉
US20100227920A1 (en) 2008-09-29 2010-09-09 The Regents Of The University Of California Aldehyde dehydrogenase inhibitors as novel depigmenting agents
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010094491A1 (en) 2009-02-18 2010-08-26 Silence Therapeutics Ag Means for inhibiting the expression of ang2
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
DK2756845T3 (en) 2009-04-03 2017-06-12 Dicerna Pharmaceuticals Inc Methods and compositions for specific inhibition of KRAS with asymmetric double stranded RNA
WO2011019887A2 (en) 2009-08-14 2011-02-17 Massachusetts Institute Of Technology Waveguide coupler having continuous three-dimensional tapering
KR101207561B1 (ko) 2009-12-15 2012-12-04 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 siRNA 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
WO2011140659A1 (en) 2010-05-12 2011-11-17 Centre Hospitalier De L'universite De Montreal Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agents
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
JP5795072B2 (ja) 2010-10-22 2015-10-14 ソンギュングヮン ユニバーシティ ファウンデーション フォー コーポレート コラボレーション Rna干渉を誘導する核酸分子及びその用途
US20130324591A1 (en) * 2010-12-06 2013-12-05 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP2658981B1 (en) 2010-12-29 2016-09-28 F.Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
WO2012118911A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
CN102719432B (zh) 2011-03-29 2013-10-23 南京大学 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
KR101590586B1 (ko) 2011-05-30 2016-02-01 성균관대학교산학협력단 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 rna
CA2842034C (en) 2011-07-18 2023-09-05 University Of Kentucky Research Foundation Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
JP6139671B2 (ja) * 2012-05-22 2017-05-31 オリックス ファーマシューティカルズ インコーポレイテッドOlix Pharmaceuticals Inc. 細胞内貫通能を持ってrna干渉を誘導する核酸分子およびその用途
US9611473B2 (en) * 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
CN105683377B (zh) 2013-07-05 2019-05-21 柏业公司 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构、含有它们的组合物用于预防或治疗呼吸疾病
EP3027223A1 (en) * 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts 十分に安定化された非対称sirna
KR102772402B1 (ko) 2015-07-27 2025-02-26 올릭스 주식회사 멜라닌 생성을 억제하는 rna 복합체
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ,インコーポレーテッド MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療
KR102825945B1 (ko) 2016-02-02 2025-06-30 올릭스 주식회사 Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
EP3411480A4 (en) 2016-02-02 2020-01-22 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4R , TRPA1, OR F2RL1
CN105748782A (zh) * 2016-02-25 2016-07-13 太和县中医院 一种用于治疗颈椎病的中药口服液
KR102339886B1 (ko) 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
JP7424728B2 (ja) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Rna干渉のための長鎖の二本鎖rna

Similar Documents

Publication Publication Date Title
JP2018533956A5 (cg-RX-API-DMAC7.html)
JP7698828B2 (ja) Rnaを編集する方法および組成物
AU2022287660B2 (en) Rapamycin resistant cells
JP6768664B2 (ja) 分子の細胞内送達のためのペプチドおよびナノ粒子
JP2020533334A (ja) アポリポタンパク質C−III(APOC3)の発現を阻害するためのRNAi剤および組成物
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
KR20210061380A (ko) 17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
US20100172882A1 (en) Compositions and methods for targeted inactivation of hiv cell surface receptors
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2018529732A5 (cg-RX-API-DMAC7.html)
JP2016521556A5 (cg-RX-API-DMAC7.html)
JP2016520312A5 (cg-RX-API-DMAC7.html)
CN105658797A (zh) 用于调节rna的组合物和方法
JP2015518710A5 (cg-RX-API-DMAC7.html)
JP2017093448A5 (cg-RX-API-DMAC7.html)
JP2016522674A5 (cg-RX-API-DMAC7.html)
JP2011522036A5 (cg-RX-API-DMAC7.html)
RU2013148024A (ru) Композиции и способы ингибирования экспрессии гена tmprss6
JP2018530530A5 (cg-RX-API-DMAC7.html)
JP2015502365A5 (cg-RX-API-DMAC7.html)
JP2019503199A5 (cg-RX-API-DMAC7.html)
JP2019506862A5 (cg-RX-API-DMAC7.html)
JP2019513384A5 (cg-RX-API-DMAC7.html)
US20240309368A1 (en) Targeted rna editing by leveraging endogenous adar using engineered rnas
TW201408309A (zh) 用於治療b型肝炎及d型肝炎感染之方法